#USA #Syenex #ARTAN Bio #VivoCell #Houston,Chicago

ARTAN Bio Partners with Syenex for Advancements in Aging Therapies

In a significant move for the biotechnology field, ARTAN Bio, a company working on innovative therapeutic solutions targeting aging, has partnered with Syenex, a leading firm in genetic medicine delivery systems. This collaboration centers around the VivoCell Platform, which is designed to enhance the precision of therapeutic deliveries in the body, especially for ARTAN's cornerstone drug candidate, ARTAN-102.

The partnership, which was officially announced on June 30, 2025, seeks to streamline the pathways for bringing ARTAN-102 from laboratory proof-of-concept studies to full clinical trials. Syenex's expertise in delivering innovative therapies will aid ARTAN in efficiently deploying their codon suppressor platform, making significant strides in the battle against age-related diseases.

Focus on Precision Delivery

ARTAN Bio’s approach is centered on addressing epigenetic changes that occur as people age. These changes often lead to various age-associated diseases. The urgency of effective treatment makes precision in drug delivery vital to achieving successful outcomes. With the VivoCell Platform, ARTAN is optimistic about enhancing the delivery mechanisms of ARTAN-102, thereby improving its efficacy.

Dr. Michael Torres, Chief Scientific Officer of ARTAN Bio, emphasized the importance of this collaboration, stating, “Precise, efficient delivery is critical to maximizing the potential of ARTAN-102.” He highlighted Syenex’s proven ability to innovate within the field of drug delivery as a key aspect of their partnership.

On the other side, Jay Rosanelli, CEO of Syenex, reinforced the potential of their joint efforts, noting, “By combining ARTAN's robust preclinical data on ARTAN-102 with our cutting-edge VivoCell Platform, we aim to shorten development timelines and expand treatment opportunities for aging and age-related diseases.” Their shared vision is to facilitate a faster transition from conceptualization to clinical reality.

Collaboration's Scope and Benefits

The agreement outlines several core areas of collaboration with a focus on:

• - Rapid Prototyping: ARTAN will gain access to a full spectrum of precision delivery components through the VivoCell Platform, which will be supported by pre-clinical scale prototyping and production capabilities of Syenex.
• - Manufacturing Scale-Up: Following the prototyping phase, developmental prototypes will be transitioned to Syenex's contract development and manufacturing organization (CDMO) partners for Good Manufacturing Practice (GMP) scale-up.
• - Option Rights: The partnership includes a non-exclusive license option for the clinical delivery vehicle, which will allow ARTAN to explore different avenues for its therapeutic development.

While financial terms of the partnership have not been disclosed, the collaboration underscores a broader trend in the biotechnology landscape where companies are leveraging each other’s strengths to tackle complex health issues.

The Future of Aging Therapeutics

Both ARTAN Bio and Syenex are positioned to contribute significantly to the future of aging therapeutics. ARTAN Bio, with an emphasis on restoring the functionality of critical proteins altered by the aging process, remains committed to addressing urgent health issues with its community-backed research initiatives. Meanwhile, Syenex, established as an open-science platform in 2022, aims to revolutionize how genetic medicines are developed, showcasing a portfolio rich with potential therapeutic applications.

As the landscape of medical therapy for aging continues to evolve, partnerships like this one may pave the way for not only innovative treatments but also improved quality of life for an aging population. The collaboration holds promise, particularly as ARTAN moves towards clinical trials, building on the insights from successful delivery technology.

For those interested in following developments regarding their progress, further information can be found on their respective websites: ARTAN Bio and Syenex.